MAX-4 is under clinical development by MaxiNovel Pharmaceuticals and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to GlobalData, Phase I drugs for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MAX-4’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MAX-4 overview
MAX-4 is under development for the treatment of myelodysplastic syndrome, acute myelocytic leukemia, relapsed/refractory acute myeloid leukemia, solid tumors, small-cell lung cancer. The drug candidate is formulated as a capsule and administered through the oral route. It acts by targeting FMS like tyrosine kinase 3 (FLT3) and fibroblast growth factor receptor (FGFR).
It was also under development for the treatment of metastatic colorectal cancer, gastric cancer and adenocarcinoma of the gastroesophageal junction.
MaxiNovel Pharmaceuticals overview
MaxiNovel Pharmaceuticals is a biotechnology company that specializes in developing small molecule drugs focus in the areas of blood tumors, solid tumors and autoimmune diseases. The company is headquartered in Shanghai City, Shanghai, China.
For a complete picture of MAX-4’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
